UNSPSC 51111829: Abarelix

This classification denotes a gonadotropin releasing hormone inhibitor with the molecular formula C72H95ClN14O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W486SJ5824, chemically known as d-alaninamide, n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-n-methyl-l-tyrosyl-d-asparaginyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl- 10 but generally known as abarelix, which bears US NIH Compound Identifier 16131215.

UNSPSC 51111829 Abarelix is a Commodity code covering the procurement of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist pharmaceutical used in the treatment of advanced prostate cancer. State and local governments purchase this drug primarily through public health departments, state Medicaid agencies, correctional health systems, and hospital networks to support oncology treatment programs and inmate medical care. The drug is typically procured via competitive bid or established pharmaceutical contracts through group purchasing organizations and state formulary programs, with quantities and dosing determined by patient population and clinical protocols.

The source provided contains no recent state and local contract opportunities tagged to this code, so current procurement activity cannot be characterized by issuing body, geography, or representative recent solicitations. The absence of posted opportunities under this code may reflect the specialized nature of pharmaceutical procurement — abarelix is often sourced through standing state health-system contracts, group purchasing agreements, or direct manufacturer relationships rather than public RFP or IFB processes.